Kirin Holdings Company, Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kirin Holdings Company, Limited (KNBWY), a leading Japanese beverage and health sciences holding company founded in 1907 and headquartered in Nakano-ku, Tokyo, develops group-wide management strategies and oversees operations across food and beverages, pharmaceuticals, and health science domains. The company produces and markets a diverse portfolio of products including flagship beers such as Kirin Ichiban and Kirin Lager; non-alcoholic beverages like Kirin Mets, Gogo no Kocha tea, Kirin Lemon, and healthy soft drinks; wines and spirits including Four Roses; soft drinks, dairy products, margarine, jams, and honey; as well as pharmaceuticals and biopharmaceuticals through its subsidiary Kyowa Kirin, which focuses on antibody drugs sold in around 50 countries, and health science offerings leveraging fermentation technology in plant genetics and bioengineering. Kirin Holdings operates primarily in Japan with significant presence in Asia, Oceania, North America, and the Philippines via a 48% stake in San Miguel Brewery, managing a chain of Kirin City beer pubs and targeting consumers across life stages with products emphasizing quality, sustainability, and health benefits. In recent developments, the company initiated the sale of its Four Roses bourbon brand in October 2025 for approximately $1 billion to reallocate capital toward health sciences; pursued strategic growth in health science through acquisitions in Asia-Pacific during fiscal 2023-2024, including bolstering its FANCL integration for CRM enhancements and cost reductions starting in fiscal 2028; formed a global collaboration with Kura Oncology in November 2024 for the development and commercialization of ziftomenib in acute leukemias, with FDA priority review accepted; and continues its pivot toward health-oriented beverages and pharmaceuticals amid inflationary pressures and portfolio optimization, reporting consolidated revenue of 2,338,385 million yen for the fiscal year ended December 31, 2024.
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Kyowa Kirin stops development of skin condition treatment
3 Reasons Growth Investors Will Love Kirin (KNBWY)
Kirin (KNBWY) Upgraded to Buy: What Does It Mean for the Stock?
Is Kirin (KNBWY) Stock Undervalued Right Now?
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Should Value Investors Buy Kirin (KNBWY) Stock?
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Is Kirin (KNBWY) Stock Outpacing Its Consumer Staples Peers This Year?
Are Investors Undervaluing Kirin (KNBWY) Right Now?
Kirin (KNBWY) Expected to Announce Earnings on Thursday